Abstract
Angiogenesis and vasculogenesis, regulated by VEGF/VEGFR signaling pathways, play key roles in tumor growth and metastasis. Selective inhibition of VEGFR kinase has been explored as a highly successful clinical strategy in cancer treatment. A number of VEGFR inhibitors have been approved in clinical use and many more are in various stages of drug development. This paper reviews selective small-molecule VEGFR inhibitors in clinical uses and in clinical trials, with particular focus on in vitro, in vivo and clinical trial results of these inhibitors. The VEGF/VEGFR genes and signaling pathways involved in tumor angiogenesis, and the strategies for accessing and improving the therapeutic efficacy of VEGFR inhibitors are also discussed.
Keywords: Selective, VEGFR inhibitor, anticancer, angiogenesis, vasculogenesis, tumor growth, metastasis, clinical trials, signaling pathways, growth factors
Current Pharmaceutical Design
Title:Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Volume: 18 Issue: 20
Author(s): Cunlong Zhang, Chunyan Tan, Huaiwei Ding, Tian Xin and Yuyang Jiang
Affiliation:
Keywords: Selective, VEGFR inhibitor, anticancer, angiogenesis, vasculogenesis, tumor growth, metastasis, clinical trials, signaling pathways, growth factors
Abstract: Angiogenesis and vasculogenesis, regulated by VEGF/VEGFR signaling pathways, play key roles in tumor growth and metastasis. Selective inhibition of VEGFR kinase has been explored as a highly successful clinical strategy in cancer treatment. A number of VEGFR inhibitors have been approved in clinical use and many more are in various stages of drug development. This paper reviews selective small-molecule VEGFR inhibitors in clinical uses and in clinical trials, with particular focus on in vitro, in vivo and clinical trial results of these inhibitors. The VEGF/VEGFR genes and signaling pathways involved in tumor angiogenesis, and the strategies for accessing and improving the therapeutic efficacy of VEGFR inhibitors are also discussed.
Export Options
About this article
Cite this article as:
Zhang Cunlong, Tan Chunyan, Ding Huaiwei, Xin Tian and Jiang Yuyang, Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials, Current Pharmaceutical Design 2012; 18 (20) . https://dx.doi.org/10.2174/138161212800672732
DOI https://dx.doi.org/10.2174/138161212800672732 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
Protein & Peptide Letters Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells
Mini-Reviews in Medicinal Chemistry Inhibition of the Tissue Factor Coagulation Pathway
Current Vascular Pharmacology Role of NF-κB in the Regulation of Cytochrome P450 Enzymes
Current Drug Metabolism Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry Overview of Cantharidin and its Analogues
Current Medicinal Chemistry Renaissance of the Biologically Active Vitamin A Derivatives: Established and Novel Directed Therapies for Cancer and Chemoprevention
Current Pharmaceutical Design Radionuclide Molecular Imaging Using Affibody Molecules
Current Pharmaceutical Biotechnology The Association of Chemotherapy and Radiotherapy in Squamous Cell Carcinoma of Anal Canal
Current Drug Therapy Role of Radiopharmaceuticals in Development of Inhaled Drugs
Current Pharmaceutical Design Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas
Current Cancer Drug Targets Current Drug Therapy for Prostate Cancer: An Overview
Current Medicinal Chemistry - Anti-Cancer Agents Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs
Anti-Cancer Agents in Medicinal Chemistry Evolutioninthe Pharmacogenetics and Pharmacogenomics of Inflammatory Bowel Disease - Order Slowly Rises from the Chaos
Current Pharmacogenomics The Application of Stimuli-responsive Nanocarriers for Targeted Drug Delivery
Current Topics in Medicinal Chemistry Recent Developments in CE-MS Based Metabolomics
Current Analytical Chemistry Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal